Expected Outcomes of Pulmonary rehabilitation

Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum

Chronic respiratory diseases

- Increasingly important causes of morbidity and mortality in the modern world
- COPD

most common chronic lung diseases major cause of lung-related death and disability

Pulmonary rehabilitation (PR) recommended standard of care for patients with chronic lung disease



The clinical course of COPD, showing the vicious cycle that ensues and some of the association with systemic consequences and comorbidities

Effects of Exercise impairment in COPD

Survival in COPD



Midthigh muscle cross-sectional area is a better predictor of mortality than BMI in patients with COPD

TABLE 3. PREDICTORS OF MORTALITY: MULTIVARIATE ANALYSIS									
	Hazard R	atio	95% Cl	p Value					
$MTCSA_{CT} < 70 \text{ cm}^2$	3.68		1.52-8.09	0.0038					
$FEV_1 < 50\%$ predicted	4./0		1.12-20.54	0.0542					
Definition of abbreviations: CI = confidence interval; MTCSA _{CT} = midthigh muscle cross- sectional area obtained by CT scan									
sectional area obtained by CT sca									
sectional area obtained by CT sca									
TABLE 4. INTERACTION B	ETWEEN	Fev ₁ and	MTCSA _{CT}						
TABLE 4. INTERACTION B	ETWEEN	FEV₁ AND No Deaths/	MTCSA _{CT}						
TABLE 4. INTERACTION B	ETWEEN	FEV ₁ AND No Deaths/ N of Patients	MTCSA _{CT} Hazard Ratio	95% Cl					
TABLE 4. INTERACTION B FEV ₁ \geq 50% and MTCSA _{CT} \geq 3	ETWEEN	FEV ₁ AND No Deaths/ N of Patients 1/29	MTCSA _{CT} Hazard Ratio 1 (referent)	95% Cl					
FEV ₁ \ge 50% and MTCSA _{CT} \ge 3 FEV ₁ \ge 50% and MTCSA _{CT} \ge 3	ETWEEN	FEV ₁ AND No Deaths/ N of Patients 1/29 1/16	MTCSA _{CT} Hazard Ratio 1 (referent) 2.14	95% Cl 0.13–34.4					
sectional area obtained by CT sca TABLE 4. INTERACTION B FEV ₁ \geq 50% and MTCSA _{CT} \geq 3 FEV ₁ \geq 50% and MTCSA _{CT} $<$ 3 FEV ₁ \leq 50% and MTCSA _{CT} \geq 3	*** ETWEEN 70 cm ² 70 cm ² 70 cm ²	FEV ₁ AND No Deaths/ N of Patients 1/29 1/16 6/51	MTCSA _{CT} Hazard Ratio 1 (referent) 2.14 3.37	95% Cl 					



Marquis K, AJRCCM 2002;166:809-813

Multivariate adjusted risk factors of readmission to hospital for an exacerbation in a cohort of 312 patients with COPD

	Adjusted HR (95% CI)	p value
≥3 COPD admissions in the year before recruitment*	1.66 (1.16 to 2.39)	0.006
% predicted FEV ₁	0.97 (0.96 to 0.99)	0.001
Po ₂ (kPa)	0.88 (0.79 to 0.98)	0.024
Controlled by a:		
General practitioner	1.00	
Pulmonologist	1.66 (0.98 to 2.80)	0.058
Anticholinergics	1.81 (1.11 to 2.94)	0.017
Usual physical activity (in tertiles):		
<79 kcal/day	1.00	
79–232 kcal/day	0.87 (0.60 to 1.27)	0.469
>232 kcal/day	0.54 (0.34 to 0.86)	0.010

Garcia-Aymerich J. Thorax. 2003;58:100-105

Our Most Successful Interventions for Improving Exercise Tolerance in COPD

• Pulmonary rehabilitation

Improves peripheral muscle function

• Bronchodilator

Improves lung function

Definition of pulmonary rehabilitation

• From the ATS in 2006

- Evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory disease who are symptomatic and often have decreased daily life activities.
- Integrated into the individualized treatment of the patient, pulmonary rehabilitation is designed to reduce symptoms, optimize functional status, increase participation, and reduce health care costs through stabilizing or reversing systemic manifestations of the disease

Pulmonary rehabilitation (PR)

Patient assessment
Exercise and physical training
Education
Nutritional intervention
Psychological support

Patient selection

 Functional status COPD patients at all stage of disease • Severity of dyspnea MRC grade 5 ; not benefit Motivation highly motivated patients ; especially important in the case of outpatient Smoking status No evidence; smokers will benefit less than nonsmokers continuing smokers ; less likely to complete rehabilitation than nonsmokers (evidence B)

Contraindication to exercise testing

- A recent significant change in the resting EKG suggesting significant ischemia, recent MI (within 2 days), or other acute cardiac event
- Unstable angina
- Uncontrolled cardiac arrhythmia
- Severe symptomatic aortic stenosis
- Uncontrolled symptomatic heart failure
- Acute pulmonary embolius or pulmonary infartion
- Acute myocarditis or pericarditis
- Suspected or known dissecting aneurysm
- Acute infection



Exercise programs

Maximal cardiopulmonary exercise test

 assess the safety of exercise
 the factors contributing to exercise limitation
 the exercise prescription

 Program duration and frequency

 At least 3 times for week
 minimum length of an effective program ; 6 weeks
 longer programs yield larger more training effects

Functional exercise capacity -program duration < 6 months

Study		Rehab		No exercise	Weighted Mean Difference (Random	n) Weight	Weighted Mean Difference (Random)
	N	Mean(SD)	Ν	Mean(SD)	95% CI	(%)	95% CI
Booker 1984	32	21.00 (85.00)	37	5.00 (90.00)		20.7	16.00 [-25.33, 57.33]
Cambach 1997	12	51.00 (89.00)	7	46.00 (79.00)		10.7	5.00 [-72.21, 82.21]
Goldstein 1994	36	32.00 (102.00)	41	-11.00 (99.00)		19.4	43.00 [-2.04, 88.04]
Lake 1990	7	108.60 (79.00)	7	-35.00 (50.00)		12.4	143.60 [74.34, 212.86]
Ringbaek 2000	17	10.47 (85.09)	19	-18.52 (77.50)		16.6	28.99 [-24.40, 82.38]
Simpson 1992	14	36.00 (102.00)	14	7.00 (120.00)		9.8	29.00 [-53.50, 111.50]
Wijkstral 1994	28	9.00 (87.00)	15	-28.00 (141.00)		10.5	37.00 [-41.29, 115.29]
Total (95% CI)	146		140			100.0	41.44 [10.70, 72.18]
Test for heterogeneit	ty chi-so	quare=10.92 df=6	p=0.09	1?? =45.1%			
Test for overall effect	t z=2.64	4 p=0.008					

-100.0 -50.0 50.0 100.0 Favours control

Favours treatment

Functional exercise capacity -program duration => 6 months

Study		Rehab	No exercise		Weighted Mean Difference (Random)		Weight	Weighted Mean Difference (Random)
	N	Mean(SD)	N	Mean(SD)		95% CI	(%)	95% CI
Engstr??m 1999	26	38.00 (90.00)	24	-2.00 (102.00)	-		23.8	40,00 [-13.50, 93.50]
Gosselink 2000	34	58.00 (125.00)	28	3.00 (104.00)	+	—	2.1.0	55.00 [-2.00, 2.00]
G?/ell 1995	29	91.00 (67.00)	27	8.00 (67.00)			55.2	83.00 [47.88, 118.12]
Total (95% CI)	89		79			-	100.0	66.90 [40.80, 93.00]
Test for heterogenei	ty chi-s	quare=1.95 df=2 p	=0.38	?? =0.0%				
Test for overall effect	t z—5.0	2 p≪0.00001						
					100.0 50.0 0	50.0 100.0		

Cochrane database 2001, CD003793

Exercise programs

Intensity of Exercise

• High vs Low intensity

- > 60% of the peak exercise capacity some physiologic training effects
 Symptom scores (dyspned or fatious)
- Symptom scores (dyspnea or fatigue)
 - \rightarrow Borg score : 4 to 6

Exercise programs

 Endurance and strength training
 Endurance training (cycling or walking) Intensity (60% maximal work rate).
 > 30 minutes Interval training

 Strength or resistance training two to four sets of 6 to 12 repetitions (50 to 85% of one repetition maximum)

Practice guidelines

- 1. A minimum of 20 sessions, three times per week
- High-intensity exercise produces greater physiologic benefit however, low-intensity training is also effective
- 3. Both upper and lower extremity training should be utilized.
- 4. The combination of endurance and strength training generally has multiple beneficial effects
- 5. Interval training may be useful in more symptomatic patients

Nutrition counseling

Nutritional counseling

- 25% of patients with COPD (stage II-IV)
 : reduction in body mass index and fat free mass
 Reduction of BMI
 : independent risk factor for mortality in COPD
 Breathless while eating
 : take small, frequent meals
- Poor dentition should be corrected and comorbidities should be managed appropriately.

Nutritional counseling

- Improving the nutritional state of COPD who are losing weight can be improved respiratory muscle strength.
- Controversy remains to whether this additional effort is cost effective.
- Nutritional supplementation alone may not be a sufficient strategy.

Anabolic steroids in COPD with weight loss

: increase body weight and lean body mass but have little or no effect on exercise capacity

Education

Patient Education

- Smoking cessation and reducing risk factors
- Learning about the causes and clinical outlook of COPD
- Inhalers and medications
- Exacerbation
- Strategies to minimize dyspnea
- Complication ; cor pulmonale and cachexia
- Oxygen therapy
- End of life

Breathing Strategies

Pursed-lip breathing
Active expiration
Diaphragmatic breathing
Specific body positions
Coordinating paced breathing with activities.



Diaphragmatic breathing (복식호흡)



Body positions to reduce shortness of breath

Sitting positions

Standing positions



Lean your chest forward slightly. This will lessen pressure against your diaphragm allowing it to relax more.

Six principles of energy conservation

- Prioritize your activities
- Plan your schedule within your limits
- Pace yourself
- Positioning
- Pursed-lip breathing
- Positive attitude

Self-Management Education

• Core component of comprehensive PR



Assessment and follow-up

- Detailed history and physical examination
- Spirometry (PFT with BDR)
 - establishing entry suitability and baseline
 status but not used in outcome assessment
- Assessment of exercise capacity
- Measurement of health status and impact of breathlessness
- Assessment of inspiratory and expiratory muscle strength and lower limb strength in patients who suffer from muscle wasting

Benefits of pulmonary rehabilitation in COPD

Evidence A

Improves exercise capacity

Reduces the perceived intensity of breathlessness

Improve health-related quality of life

Reduces the number of hospitalizations and days in the hospital

Reduces anxiety and depression associated with COPD

Benefits of pulmonary rehabilitation in COPD

Evidence B

Strength and endurance training of the upper limbs improves arm function

Benefits extend well beyond the immediate period of training

Improves survival

Benefits of pulmonary rehabilitation in COPD

Evidence C

Respiratory muscle training is beneficial, especially when combined with general exercise training.

Psychosocial intervention is helpful.

Evidence A ; Randomized controlled trials, rich body of data Evidence B ; Randomized controlled trials, limited body of data Evidence C ; Nonrandomized trials, observational studies

Location of Pulmonary Rehabilitation

Inpatient PR
 Out-patient based PR
 Home-based PR

Home vs center based physical activity programs in older adults Quality of life

Study	Home-based n/N	Center based n/N	Odds Ratio (Random) 95% Cl	Weight (96)	Odds Ratio (Random) 95% Cl
01 After program					
Strijbos 1996	11/15	12/15		100.0	0.69 [0.12, 3.79]
Subtotal (95% CI)	15	15		100,0	0.69 [0.12, 3.79]
Total events: 11 (Home	-based). 12 (Center-based)			
Test for heterogeneity, r	not applicable				
Test for overall effect z=	:0.43 p=0.7				
02 18 months					
Strijbos 1996	8/13	9/14		100,0	0.89 [0.19, 4.24]
Subtotal (95% CI)	13	1		100,0	0.89 [0.19, 1.21]
Total events: 8 (Home-b	ased), 9 (Center-based)				
Test for heterogeneity, r	not applicable				
Test for overall effect z=	:0.15 p=0.9				
			0.1 0.2 0.5 1 2 5 10		
			Favours center Favours home		

Cochrane database 2005, CD004017

A simple and easy home-based pulmonary rehabilitation programme for patients with chronic lung diseases

Na JO et al Monaldi Arch Chest Dis 2005;63:30-36

Table 3. - Changes in the Exercise Endurance, 6 Minute Walking

Variables	Rehabilitation Group						
	Baseline	12 weeks	p value				
Lower extremity Duration (min)	8.2 ± 3.5	14.0 ± 4.5	Ø.001				
Work (Watts)	41.5 ± 17.5	46.5 ± 19.0	0.005				
Upper extremity Duration (min)	5.9 ± 3.2	6.8 ± 3.4	0.001				
Work (Watts) 6 min walk(m) Mean SaO ₂ * Min SaO ₂ ** MIP (cm H ₂ O)	$\begin{array}{r} 16.2 \pm 8.0 \\ 470.7 \pm 63.2 \\ 89.9 \pm 5.50 \\ 86.1 \pm 7.12 \\ 80.0 \pm 29.5 \end{array}$	$\begin{array}{c} 19.7\pm8.5\\ 508.4\pm61.1\\ 88.5\pm5.94\\ 83.8\pm7.66\\ 103.5\pm35.2\end{array}$	0.001 0.001 NS NS 0.001				

Home-based PR in Korea

	Reha	bilitation gro	up	C	Control group			
Variables	Baseline	12 weeks	p value	Baseline	12 weeks	<i>p</i> value		
WR max (watts)	53.3 ± 11.7	58.4 ± 11.9	NS	58.2 ± 24.4	60.1 ± 23.5	NS		
VO2 max (L/min)	0.75 ± 0.20	0.80 ± 0.22	NS	0.85 ± 0.31	0.84 ± 0.29	NS		
AT (L/min)	0.64 ± 0.18	0.64 ± 0.26	NS	0.84 ± 0.21	0.77 ± 0.22	NS		
O_2 pulse (ml/beat)	7.02 ± 1.35	6.68 ± 1.58	NS	8.2 ± 5.1	6.9 ± 2.2	NS		
HR max (beats/min)	126.0 ± 19.1	132.4 ± 17.9	NS	134.1 ± 28.1	133.7 ± 23.1	NS		
V_{E} max (L/min)	34.1 ± 9.6	36.0 ± 10.1	NS	32.4 ± 11.5	31.8 ± 9.1	NS		
Lower extremity Duration (sec)	6.89 ± 3.6	14.8 ± 3.7	0.002	9.1 ± 2.8	10.4 ± 3.0	NS		
Work (Joule)	37.2 ± 7.5	41.1 ± 8.6	0.01	37.8 ± 16.4	41.7 ± 17.3	0.043		
Upper extremity Duration (sec)	$5.3\pm\!1.6$	6.2 ± 2.2	0.02	6.3 ± 4.4	$5.7\pm\!3.9$	NS		
Work (Joule)	15.6 ± 4.6	19.4 ± 5.3	0.001	18.3 ± 11.5	17.8 ± 9.7	NS		

Yoon SH et al. Tuber Resp Dis 2002;52:597-607

Home-based PR in Korea

	Reha	bilitation grou	p	Control group			
Variables	Baseline	12 weeks	p value	Baseline	12 weeks	p value	
6 min walk (m)	464.9 ± 59.8	508.4 ± 37.2	0.003	490.8 ± 66.3	513.4 ± 56.6	NS	
MIP (cmH ₂ O)	72.8 ± 27.2	93.7 ± 36.6	0.012	91.4 ± 30.9	100.2 ± 32.9	NS	
Score	Baseline	12 weeks	p value	Baseline	12 weeks	🌶 value	
Symptom	47.9 ± 20.6	45.4 ± 21.1	NS	50.0 ± 19.3	48.9 ± 23.0	NS	
Activity	68.5 ± 19.2	55.0 ± 14.9	0.008	62.5 ± 14.6	64.5 ± 19.6	NS	
Impact	39.4 ± 18.7	21.8 ± 12.3	0.001	38.6 ± 13.5	33.3 ± 13.2	0.02	
Total	49.6 ± 16.7	35.7 ± 12.0	0.001	47.7 ± 11.7	45.3 ± 14.5	NS	

Yoon SH et al. Tuber Resp Dis 2002;52:597-607

Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease (Review)

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2009, Issue 1

Figure 2. Forest plot of comparison: I Rehabilitation versus control, outcome: I.I Hospital admission (to end of follow-up).

	Experim	ental	Contr	rol		Odds Ratio	Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	:I M-H, Fix	ed, 95% Cl	
Behnke 2000	3	14	9	12	34.0%	0.09 (0.01, 0.56) 		
Man 2004	2	20	12	21	47.1%	0.08 (0.02, 0.45	j —		
Murphy 2005	2	13	5	13	18.9%	0.29 (0.04, 1.90]	-	
Total (95% CI)		47		46	100.0%	0.13 [0.04, 0.35	•		
Total events	7		26						
Heterogeneity: Chi² =	1.11, df = 1	2 (P = 0	.57); ² =	0%					-
Test for overall effect:	Z = 3.98 (F	° < 0.00	101)				Favours experimental	Favours contro	000

Figure 4. Forest plot of comparison: I Rehabilitation versus control, outcome: I.2 Mortality.

	Experim	ental	Contr	rol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Behnke 2000	1	14	1	12	7.8%	0.85 [0.05, 15.16]	
Man 2004	1	20	2	21	14.4%	0.50 (0.04, 5.99)	••
Troosters 2000	6	24	12	19	77.9%	0.19 (0.05, 0.72)	
Total (95% CI)		58		52	100.0%	0.29 [0.10, 0.84]	•
Total events	8		15				
Heterogeneity: Chi² =	: 1.07, df =)	2 (P = 0	.59); ² =	0%			
Test for overall effect	: Z = 2.29 (F	P = 0.02	!)				Favours experimental Favours control

Evidence from small studies of moderate methodological quality suggests that pulmonary rehabilitation is a highly effective and safe intervention to reduce hospital admissions and mortality and to improve health-related quality of life in COPD patients after suffering an exacerbation.

Thank you for your attention !!!!

